US4965199A
(en)
*
|
1984-04-20 |
1990-10-23 |
Genentech, Inc. |
Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
|
KR910006424B1
(ko)
*
|
1985-08-21 |
1991-08-24 |
인코텍스 비.브이 |
편성브리프(brief) 제조방법
|
US5198349A
(en)
*
|
1986-01-03 |
1993-03-30 |
Genetics Institute, Inc. |
Method for producing factor VIII:C and analogs
|
FI98829C
(fi)
*
|
1986-01-27 |
1997-08-25 |
Chiron Corp |
Menetelmä rekombinoidun proteiinikompleksin valmistamiseksi, jolla on humaanitekijä VIII:C-aktiivisuutta
|
US5595886A
(en)
*
|
1986-01-27 |
1997-01-21 |
Chiron Corporation |
Protein complexes having Factor VIII:C activity and production thereof
|
US5422260A
(en)
*
|
1986-05-29 |
1995-06-06 |
Genetics Institute, Inc. -Legal Affairs |
Human factor VIII:c muteins
|
US5451521A
(en)
*
|
1986-05-29 |
1995-09-19 |
Genetics Institute, Inc. |
Procoagulant proteins
|
IL84168A0
(en)
*
|
1986-10-15 |
1988-03-31 |
Rorer Int Overseas |
Human factor viii-c analogs,process for the preparation thereof and pharmaceutical compositions containing the same
|
US6060447A
(en)
*
|
1987-05-19 |
2000-05-09 |
Chiron Corporation |
Protein complexes having Factor VIII:C activity and production thereof
|
US5171844A
(en)
|
1987-06-12 |
1992-12-15 |
Gist-Brocades N.W. |
Proteins with factor viii activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
|
US6346513B1
(en)
|
1987-06-12 |
2002-02-12 |
Baxter Trading Gmbh |
Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
|
AU627150B2
(en)
*
|
1987-06-12 |
1992-08-20 |
Immuno Ag |
Novel proteins with factor viii activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
|
EP0294910B1
(en)
*
|
1987-06-12 |
1996-09-11 |
Immuno Ag |
Novel proteins with factor VIII activity, process for their preparation using genetically engineered cells and pharmaceutical compositions containing them
|
FR2619314B1
(fr)
*
|
1987-08-11 |
1990-06-15 |
Transgene Sa |
Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
|
JPH0387173A
(ja)
*
|
1987-09-10 |
1991-04-11 |
Teijin Ltd |
ヒト活性化天然型ファクター8cの製造方法及びそれに用いる形質転換体
|
DE69032043T2
(de)
*
|
1989-11-17 |
1998-06-04 |
Chiron Corp |
Proteinkomplexe mit faktor viii:c-aktivität und deren herstellung
|
US20050209121A1
(en)
*
|
1990-12-05 |
2005-09-22 |
Novozymes A/S |
Proteins with changed epitopes and methods for the production thereof
|
US20060122376A1
(en)
*
|
1991-02-07 |
2006-06-08 |
Chiron Corporation |
Protein complexes having factor VIII:C activity and production thereof
|
US5661008A
(en)
*
|
1991-03-15 |
1997-08-26 |
Kabi Pharmacia Ab |
Recombinant human factor VIII derivatives
|
US5663060A
(en)
*
|
1992-04-07 |
1997-09-02 |
Emory University |
Hybrid human/animal factor VIII
|
US5888974A
(en)
*
|
1992-04-07 |
1999-03-30 |
Emory University |
Hybrid human/animal factor VIII
|
US6180371B1
(en)
*
|
1996-06-26 |
2001-01-30 |
Emory University |
Modified factor VIII
|
US5364771A
(en)
*
|
1992-04-07 |
1994-11-15 |
Emory University |
Hybrid human/porcine factor VIII
|
US5744446A
(en)
*
|
1992-04-07 |
1998-04-28 |
Emory University |
Hybrid human/animal factor VIII
|
DK53792D0
(da)
*
|
1992-04-24 |
1992-04-24 |
Novo Nordisk As |
Fremgangsmaade til fremstilling af proteiner
|
WO1993025712A1
(en)
*
|
1992-06-15 |
1993-12-23 |
The Regents Of The University Of California |
Screening assay for the identification of immunosuppressive drugs
|
US5563045A
(en)
|
1992-11-13 |
1996-10-08 |
Genetics Institute, Inc. |
Chimeric procoagulant proteins
|
DE69434689D1
(de)
*
|
1993-06-10 |
2006-05-18 |
Genetic Therapy Inc |
Adenovirale vektoren für die behandlung der hämophilie
|
SE504074C2
(sv)
*
|
1993-07-05 |
1996-11-04 |
Pharmacia Ab |
Proteinberedning för subkutan, intramuskulär eller intradermal administrering
|
AU7254894A
(en)
*
|
1993-07-23 |
1995-02-20 |
Baxter International Inc. |
Activated human factor viii and method of preparation
|
US5576291A
(en)
*
|
1993-09-13 |
1996-11-19 |
Baxter International Inc. |
Activated factor VIII as a therapeutic agent and method of treating factor VIII deficiency
|
US7041801B1
(en)
|
1995-06-07 |
2006-05-09 |
Vanderbilt University |
Antibodies binding to polypeptides encoded by developmentally-regulated endothelial cell locus-1
|
US5874562A
(en)
*
|
1995-06-07 |
1999-02-23 |
Progenitor, Inc. |
Nucleic acid encoding developmentally-regulated endothelial cell locus-1
|
US5910481A
(en)
*
|
1995-11-13 |
1999-06-08 |
Immuno Ag |
Hybrid proteins with modified activity
|
US20040092442A1
(en)
*
|
1996-04-24 |
2004-05-13 |
University Of Michigan |
Inactivation resistant factor VIII
|
DK1754718T3
(da)
*
|
1996-04-24 |
2011-07-18 |
Univ Michigan |
Inaktiveringsresistent faktor VIII
|
US8183344B2
(en)
|
1996-04-24 |
2012-05-22 |
University Of Michigan |
Inactivation resistant factor VIII
|
US6458563B1
(en)
*
|
1996-06-26 |
2002-10-01 |
Emory University |
Modified factor VIII
|
US7560107B2
(en)
|
1996-06-26 |
2009-07-14 |
Emory University |
Modified factor VIII
|
WO1999029848A1
(en)
*
|
1997-12-05 |
1999-06-17 |
The Immune Response Corporation |
Novel vectors and genes exhibiting increased expression
|
US7820796B2
(en)
|
1998-03-12 |
2010-10-26 |
Genetics Institute, Llc. |
Methods for producing Factor VIII proteins
|
ES2182501T3
(es)
|
1998-03-12 |
2003-03-01 |
Inst Genetics Llc |
Metodos mejorados para producir proteinas del factor viii.
|
IL142069A0
(en)
|
1998-09-21 |
2002-03-10 |
Genetics Inst |
Methods of downmodulating the immune response to therapeutic proteins
|
US6358703B1
(en)
*
|
1998-12-10 |
2002-03-19 |
Bayer Corporation |
Expression system for factor VIII
|
US6197526B1
(en)
|
1999-01-04 |
2001-03-06 |
Dyax Corp. |
Polypeptides for binding human factor VIII and fragments of human factor VIII
|
US7112438B2
(en)
*
|
1999-01-04 |
2006-09-26 |
Dyax Corp. |
Binding molecules for human factor VIII and factor VIII-like proteins
|
JP5149470B2
(ja)
|
1999-02-22 |
2013-02-20 |
バクスター・インターナショナル・インコーポレイテッド |
新規のアルブミンを含有していない第viii因子処方物
|
US6517830B1
(en)
*
|
1999-08-05 |
2003-02-11 |
Emory University |
Compositions and methods for the expression of factor VIII polypeptides and uses therefor
|
AU2002248329B2
(en)
*
|
2001-01-12 |
2007-06-28 |
The American National Red Cross |
Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor VIII
|
DE60234193D1
(de)
*
|
2001-06-14 |
2009-12-10 |
Scripps Research Inst |
Stabilisierte faktor viii mit gentechnisch konstruierten disulfidbindungen
|
JP2005511038A
(ja)
*
|
2001-11-30 |
2005-04-28 |
エモリー ユニバーシテイ |
第viii因子c2ドメインのバリアント
|
US7041635B2
(en)
|
2003-01-28 |
2006-05-09 |
In2Gen Co., Ltd. |
Factor VIII polypeptide
|
EP2338523B1
(en)
|
2003-02-26 |
2024-01-17 |
Nektar Therapeutics |
Polymer-factor viii moiety conjugates
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
EP1682106A4
(en)
*
|
2003-10-30 |
2008-06-11 |
Univ Emory |
MODIFIED FVIII WITH REDUCED IMMUNOGENICITY BY MUTAGENESIS OF A2 AND C2 EPITOPES
|
US7211559B2
(en)
*
|
2003-10-31 |
2007-05-01 |
University Of Maryland, Baltimore |
Factor VIII compositions and methods
|
PT1750733E
(pt)
*
|
2004-05-03 |
2014-02-14 |
Baxter Healthcare Sa |
Método de administração de factor viii suíno sem domínio b
|
US20060080848A1
(en)
*
|
2004-10-19 |
2006-04-20 |
Lace Charles R |
Wheel blade sight
|
EP1707634A1
(en)
|
2005-03-29 |
2006-10-04 |
Octapharma AG |
Method for isolation of recombinantly produced proteins
|
EP1739179A1
(en)
|
2005-06-30 |
2007-01-03 |
Octapharma AG |
Serum-free stable transfection and production of recombinant human proteins in human cell lines
|
GB0606190D0
(en)
|
2006-03-28 |
2006-05-10 |
Isis Innovation |
Construct
|
US7645860B2
(en)
|
2006-03-31 |
2010-01-12 |
Baxter Healthcare S.A. |
Factor VIII polymer conjugates
|
WO2008005847A2
(en)
*
|
2006-06-30 |
2008-01-10 |
The Regents Of The University Of Michigan |
Method of producing factor viii proteins by recombinant methods
|
FR2913020B1
(fr)
*
|
2007-02-23 |
2012-11-23 |
Biomethodes |
Nouveaux facteurs viii pour le traitement des hemophiles de type a
|
AU2008340304B2
(en)
|
2007-12-21 |
2016-03-03 |
Aptevo Biotherapeutics Llc |
Stabilized factor IX formulations containing trehalose
|
ES2649094T3
(es)
|
2007-12-27 |
2018-01-10 |
Baxalta GmbH |
Procedimientos de cultivo celular
|
KR100981092B1
(ko)
*
|
2008-02-29 |
2010-09-08 |
고려대학교 산학협력단 |
제8 혈액응고 인자와 폰 빌리 블란트 인자 변이체의 재조합발현 벡터 시스템
|
CA2738064C
(en)
|
2008-10-15 |
2013-03-19 |
Baxter International Inc. |
Pegylation of recombinant blood coagulation factors in the presence of bound antibodies
|
EP3178835B1
(en)
|
2009-02-03 |
2019-04-10 |
Amunix Pharmaceuticals, Inc. |
Extended recombinant polypeptides and compositions comprising same
|
CN106986933A
(zh)
|
2009-02-11 |
2017-07-28 |
阿尔布梅迪克斯医疗公司 |
白蛋白变体和缀合物
|
US8691211B2
(en)
*
|
2009-03-10 |
2014-04-08 |
Puget Sound Blood Center |
Suppression of immune response to factor VIII in hemophilia A patients
|
JP2013502458A
(ja)
|
2009-08-24 |
2013-01-24 |
アムニクス オペレーティング インコーポレイテッド |
凝固第vii因子組成物ならびにそれを製造および使用する方法
|
EP3421491A3
(en)
|
2009-10-30 |
2019-03-27 |
Albumedix Ltd |
Albumin variants
|
EP2498804A4
(en)
*
|
2009-11-13 |
2013-05-08 |
Puget Sound Blood Ct |
FACTOR VIII B CELL EPITOPARIANTS WITH REDUCED IMMUNOGENITY
|
KR101770849B1
(ko)
|
2009-12-06 |
2017-09-05 |
바이오버라티브 테라퓨틱스 인크. |
인자 FⅧ-Fc의 키메라 및 하이브리드 폴리펩티드, 및 그의 사용방법
|
WO2011075185A1
(en)
|
2009-12-18 |
2011-06-23 |
Oligasis |
Targeted drug phosphorylcholine polymer conjugates
|
WO2011095604A1
(en)
|
2010-02-04 |
2011-08-11 |
Octapharma Biopharmaceuticals Gmbh |
Half-life prolongation of proteins
|
WO2011124718A1
(en)
|
2010-04-09 |
2011-10-13 |
Novozymes A/S |
Albumin derivatives and variants
|
EP2591101B1
(en)
|
2010-07-09 |
2018-11-07 |
Bioverativ Therapeutics Inc. |
Systems for factor viii processing and methods thereof
|
NZ605400A
(en)
|
2010-07-09 |
2015-05-29 |
Biogen Idec Hemophilia Inc |
Chimeric clotting factors
|
CA2816575C
(en)
|
2010-11-05 |
2019-06-11 |
Baxter Healthcare S.A. |
A new variant of antihemophilic factor viii having increased specific activity
|
BRPI1105317A2
(pt)
|
2011-01-24 |
2013-04-30 |
Fundacco Hemoct De Ribeirco Preto |
produÇço estÁvel e em larga escala de fviii humano em linhagem celular humana sk-hep-1
|
EP2717898B1
(en)
|
2011-06-10 |
2018-12-19 |
Bioverativ Therapeutics Inc. |
Pro-coagulant compounds and methods of use thereof
|
HRP20220639T1
(hr)
|
2011-07-08 |
2022-07-08 |
Bioverativ Therapeutics Inc. |
Kimerni i hibridni polipeptidi faktora viii i postupci njihove upotrebe
|
EP2737311B1
(en)
|
2011-07-25 |
2020-12-02 |
Bioverativ Therapeutics Inc. |
Assays to monitor bleeding disorders
|
KR20140083035A
(ko)
|
2011-10-18 |
2014-07-03 |
체에스엘 베링 게엠베하 |
인자 viii의 생체이용률을 증가시키기 위한 황산화 글리코사미노글리칸과 하이알루로니다제의 병용 사용
|
CN103917554B
(zh)
|
2011-10-18 |
2017-03-08 |
杰特有限公司 |
用于改善重构后纯化的因子viii的稳定性的方法
|
JP6072810B2
(ja)
|
2011-10-18 |
2017-02-01 |
ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー |
第viii因子の生物学的利用能を改善するための硫酸化グリコサミノグリカンの使用
|
EP2780364A2
(en)
|
2011-11-18 |
2014-09-24 |
Eleven Biotherapeutics, Inc. |
Proteins with improved half-life and other properties
|
EA028309B1
(ru)
|
2012-01-12 |
2017-11-30 |
Байоджен Эмэй Инк. |
Полипептиды химерного фактора viii и их применение
|
DK2802668T3
(da)
|
2012-01-12 |
2018-11-19 |
Bioverativ Therapeutics Inc |
Fremgangsmåder til reduktion af immunogenicitet mod faktor viii hos individer, der gennemgår faktor viii-terapi
|
CA2864126A1
(en)
|
2012-02-15 |
2013-08-22 |
Biogen Idec Ma Inc. |
Recombinant factor viii proteins
|
MY188897A
(en)
|
2012-02-15 |
2022-01-12 |
Bioverativ Therapeutics Inc |
Factor viii compositions and methods of making and using same
|
ES2664328T3
(es)
|
2012-03-16 |
2018-04-19 |
Albumedix A/S |
Variantes de albúmina
|
EP4079316A1
(en)
|
2012-06-08 |
2022-10-26 |
Bioverativ Therapeutics Inc. |
Procoagulant compounds
|
EP2863940A4
(en)
|
2012-06-08 |
2016-08-10 |
Biogen Ma Inc |
CHIMERIC COAGULATION FACTORS
|
WO2014008480A2
(en)
|
2012-07-06 |
2014-01-09 |
Biogen Idec Ma Inc. |
Cell line expressing single chain factor viii polypeptides and uses thereof
|
NZ703366A
(en)
|
2012-07-11 |
2018-03-23 |
Amunix Operating Inc |
Factor viii complex with xten and von willebrand factor protein, and uses thereof
|
WO2014018777A2
(en)
|
2012-07-25 |
2014-01-30 |
Biogen Idec Ma Inc. |
Blood factor monitoring assay and uses thereof
|
US10391152B2
(en)
|
2012-10-18 |
2019-08-27 |
Bioverativ Therapeutics Inc. |
Methods of using a fixed dose of a clotting factor
|
WO2014070953A1
(en)
|
2012-10-30 |
2014-05-08 |
Biogen Idec Ma Inc. |
Methods of Using FVIII Polypeptide
|
WO2014072481A1
(en)
|
2012-11-08 |
2014-05-15 |
Novozymes Biopharma Dk A/S |
Albumin variants
|
ES2959747T3
(es)
|
2013-02-15 |
2024-02-28 |
Bioverativ Therapeutics Inc |
Gen del factor VIII optimizado
|
WO2014144549A1
(en)
|
2013-03-15 |
2014-09-18 |
Biogen Idec Ma Inc. |
Factor ix polypeptide formulations
|
PL3666283T3
(pl)
|
2013-03-15 |
2022-10-03 |
Bioverativ Therapeutics Inc. |
Formulacje polipeptydu czynnika viii
|
KR20230007555A
(ko)
|
2013-06-28 |
2023-01-12 |
바이오버라티브 테라퓨틱스 인크. |
Xten을 지닌 트롬빈 절단가능한 링커 및 이의 용도
|
EP3875106A1
(en)
|
2013-08-08 |
2021-09-08 |
Bioverativ Therapeutics Inc. |
Purification of chimeric fviii molecules
|
WO2015023891A2
(en)
|
2013-08-14 |
2015-02-19 |
Biogen Idec Ma Inc. |
Factor viii-xten fusions and uses thereof
|
WO2015035342A2
(en)
|
2013-09-08 |
2015-03-12 |
Oligasis Llc |
Factor viii zwitterionic polymer conjugates
|
WO2015070014A1
(en)
|
2013-11-08 |
2015-05-14 |
Biogen Idec Ma Inc. |
Procoagulant fusion compound
|
ES2967617T3
(es)
|
2013-12-06 |
2024-05-03 |
Bioverativ Therapeutics Inc |
Herramientas de farmacocinética poblacional y sus usos
|
IL246476B
(en)
|
2014-01-10 |
2022-06-01 |
Biogen Ma Inc |
Factor viii chimeric proteins and their uses
|
KR102382402B1
(ko)
|
2014-02-04 |
2022-04-01 |
바이오젠 엠에이 인코포레이티드 |
번역 후 변형을 강화시키기 위한 통류 방식 양이온 교환 크로마토그래피의 용도
|
MA40864A
(fr)
|
2014-10-31 |
2017-09-05 |
Biogen Ma Inc |
Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
|
CN104630131B
(zh)
*
|
2015-01-15 |
2017-08-15 |
上海交通大学 |
一种稳定表达人凝血八因子的cho细胞株及其应用
|
BR112018002150A2
(pt)
|
2015-08-03 |
2018-09-18 |
Bioverativ Therapeutics Inc |
proteínas de fusão do fator ix e métodos de fabricação e uso das mesmas
|
JP7007261B2
(ja)
|
2015-08-20 |
2022-01-24 |
アルブミディクス リミティド |
アルブミン変異体及びコンジュゲート
|
EP3167877A1
(en)
|
2015-11-12 |
2017-05-17 |
Bayer Pharma Aktiengesellschaft |
Method for the production of freeze-dried pellets comprising factor viii
|
JP6695426B2
(ja)
|
2015-11-13 |
2020-05-20 |
バクスアルタ インコーポレイテッド |
組換えfviii変異型をコードする血友病a遺伝子治療用高発現ウイルスベクター
|
WO2017083762A1
(en)
|
2015-11-13 |
2017-05-18 |
Baxalta Incorporated |
Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
|
EP3411478B1
(en)
|
2016-02-01 |
2022-06-08 |
Bioverativ Therapeutics Inc. |
Optimized factor viii genes
|
JP6877469B2
(ja)
|
2016-06-24 |
2021-05-26 |
モガム・インスティテュート・フォー・バイオメディカル・リサーチMogam Institute For Biomedical Research |
Fviiiおよびvwf因子を含むキメラタンパク質、ならびにそれらの使用
|
KR20190091292A
(ko)
|
2016-12-02 |
2019-08-05 |
바이오버라티브 테라퓨틱스 인크. |
응고 인자에 대한 면역 내성 유도 방법
|
IL308416A
(en)
|
2016-12-02 |
2024-01-01 |
Bioverativ Therapeutics Inc |
Methods for the treatment of hemophilic arthritis with the help of chimeric blood coagulation factors
|
JP7374883B2
(ja)
|
2017-08-09 |
2023-11-07 |
バイオベラティブ セラピューティクス インコーポレイテッド |
核酸分子およびその使用
|
US20200263196A1
(en)
|
2017-09-27 |
2020-08-20 |
Sigilon Therapeutics, Inc. |
Methods, compositions, and implantable elements comprising active cells
|
BR112020015228A2
(pt)
|
2018-02-01 |
2020-12-29 |
Bioverativ Therapeutics Inc. |
Uso de vetores lentivirais que expressam fator viii
|
IL312315A
(en)
|
2018-04-04 |
2024-06-01 |
Sigilon Therapeutics Inc |
Implantable particles and related methods
|
WO2019195056A1
(en)
|
2018-04-04 |
2019-10-10 |
Sigilon Therapeutics, Inc. |
Methods, compositions, and implantable elements comprising stem cells
|
EP3793588A1
(en)
|
2018-05-18 |
2021-03-24 |
Bioverativ Therapeutics Inc. |
Methods of treating hemophilia a
|
BR112021000695A2
(pt)
|
2018-07-16 |
2021-04-20 |
Baxalta Incorporated |
métodos para tratar hemofilia a e para monitorar a eficácia da terapia gênica de fator viii de hemofilia a.
|
MX2021001599A
(es)
|
2018-08-09 |
2021-07-02 |
Bioverativ Therapeutics Inc |
Moleculas de acido nucleico y sus usos para la terapia genica no viral.
|
UY38389A
(es)
|
2018-09-27 |
2020-04-30 |
Sigilon Therapeutics Inc |
Dispositivos implantables para terapia celular y métodos relacionados
|
TWI851647B
(zh)
|
2019-01-16 |
2024-08-11 |
日商武田藥品工業股份有限公司 |
用於a型血友病基因治療之編碼表現增加之重組fviii變異體的病毒載體
|
AU2020298233A1
(en)
|
2019-06-19 |
2022-01-20 |
Bioverativ Therapeutics Inc. |
Recombinant factor VIII-Fc for treating hemophilia and low bone mineral density
|
AU2020364071A1
(en)
|
2019-10-10 |
2022-05-26 |
Kodiak Sciences Inc. |
Methods of treating an eye disorder
|
CN114981299A
(zh)
|
2019-12-12 |
2022-08-30 |
武田药品工业株式会社 |
使用编码具有增加的表达的重组fviii变体的病毒载体的a型血友病的基因疗法
|
TW202208619A
(zh)
|
2020-06-24 |
2022-03-01 |
美商百歐維拉提夫治療公司 |
用於純化病毒載體之方法
|
CN117858895A
(zh)
|
2021-06-14 |
2024-04-09 |
武田药品工业株式会社 |
使用表达增强的编码重组fviii变体的病毒载体的血友病a基因疗法
|
IL310997A
(en)
|
2021-08-23 |
2024-04-01 |
Bioverativ Therapeutics Inc |
Factor VIII gene optimization
|
AU2022355088A1
(en)
|
2021-09-30 |
2024-05-16 |
Bioverativ Therapeutics Inc. |
Nucleic acids encoding factor viii polypeptides with reduced immunogenicity
|
WO2024081309A1
(en)
|
2022-10-11 |
2024-04-18 |
Sigilon Therapeutics, Inc. |
Engineered cells and implantable elements for treatment of disease
|
WO2024081310A1
(en)
|
2022-10-11 |
2024-04-18 |
Sigilon Therapeutics, Inc. |
Engineered cells and implantable elements for treatment of disease
|
WO2025008774A1
(en)
|
2023-07-05 |
2025-01-09 |
Takeda Pharmaceutical Company Limited |
Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
|